205448-66-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-chloro-7-methoxyquinoline-6-carboxylate is used as an antimicrobial agent for treating infections after burns. Its ability to inhibit the growth of bacteria and other microorganisms makes it a valuable component in wound care and burn treatment.
Used in Research and Development:
Methyl 4-chloro-7-methoxyquinoline-6-carboxylate is used as a reagent in the preparation of naphthamides, which are inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. These inhibitors play a crucial role in various biological processes, including angiogenesis, cell proliferation, and cell migration. By targeting the VEGF receptor, naphthamides can potentially be used in the development of therapeutic agents for various diseases, such as cancer and age-related macular degeneration.

Upstream product

• 205448-65-3 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid methyl ester 
• 150-75-4 N-methyl-p-aminophenol 
• 65-49-6 4-Aminosalicylic acid 
• 75-09-2 dichloromethane 
• 205448-64-2 methyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)-amino)-2-methoxybenzoate 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 

Downstream Products

• 205447-81-0 4-(4-chloro-2-fluoroanilino)-7-methoxy-6-methoxycarbonylquinoline 
• 863784-17-2 Methyl 7-methoxy-4-(2-phenyl-[1,8]naphthyridin-3-yloxy)-quinoline-6-carboxylate 
• 417723-07-0 methyl 4-(4-amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxylate 

Relevant academic research and scientific papers

MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF

The present invention relates to multi-substituted pyridone derivatives and therapeutic use thereof. In particular, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, as well as use thereof as a tyrosine kinase inhibitor, in particular, use thereof in treating a disease associated with tyrosine kinase activity. Each substituent in the formula (I) is defined as in the specification.

Lenvatinib impurity as well as preparation method and application thereof

The invention discloses a lenvatinib impurity as well as a preparation method and application thereof. The impurity is a compound as shown in a formula III which is described in the specification. Thecompound as shown in the formula III provided by the invention can be used as a reference substance for detecting related substances of lenvatinib, and is used for controlling the purity of a lenvatinib bulk drug or preparation.

PROCESS FOR THE PREPARATION OF LENVATINIB OR ITS SALTS THEREOF

The present invention provides a process for the preparation of Lenvatinib or its salts thereof. The present invention also provides a crystalline form of Lenvatinib, which is characterized by the PXRD pattern as shown in figure 1. The present invention a

NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to novel polymorphs of 4-[3-chloro-4-(N'- cyclopropyl ureido) phenoxy]-7- methoxyquinoline- 6- carboxamide methanesulfonate represented by following structural formula-1a and process for preparation thereof. Further, the pres

Thiazolidone derivative of lovatinib acid and application of thiazolidone derivative

The invention discloses 4-[3-chlorine group-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinoline formyl thiazolone and application thereof. The structure conforms the general formula (I) (please see the specification of the formula), the effica

TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

Synthetic method of anti-cancer drug lenvatinib

The invention discloses a synthetic method of anti-cancer drug lenvatinib. Lenvatinib is synthesized from the compound p-aminosalicylic acid shown as drawing 1 as a starting material with the method.Reaction conditions are mild, special reaction equipment is not needed, and the applicable range is wider. Raw materials and reagents used in the method are easily purchased from the market, and reduction of production cost is facilitated. The method is simple to operate, short in synthesis period and more suitable for large-scale industrial production of lenvatinib. The method is high in synthesis efficiency, and purity of synthesized lenvatinib is high.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Design, synthesis, and evaluation

A series of naphthyl-based compounds were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors. Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family. Numerous analogues demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compounds possessed favorable pharmacokinetic (PK) profiles. In particular, compound 48 demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice. A full account of the preparation, structure-activity relationships, pharmacokinetic properties, and pharmacology of analogues within this series is presented.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors

We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases. The inhibitory activity of this series was retained at the cellular level. Naphthamides 3, 20, and 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. Once-daily oral administration of 22 for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.